Psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) are complex conditions. They affect many people. Yet, there is a gap in understanding how these conditions are treated in real-world settings. This is especially true for biologic and targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs). These drugs are used to manage PsA and axSpA. ...
You might think genes are just complicated terms, but they can actually tell us a lot about our health. Take, for example, the MTHFR and TP53 genes. The MTHFR gene helps with how the body uses folic acid, while the TP53 gene acts like a guardian, keeping our cells healthy. A recent study in South Africa looked at how these genes might affect people with psoriatic art...
Psoriatic arthritis, or PsA, is a complex inflammatory disease that can affect joints and skin, and it often comes with other health issues. Managing PsA is crucial to control the disease, prevent damage, and improve quality of life. Over time, many drugs have been developed to help. While some, like NSAIDs and older DMARDs, have helped, it wasn't until biologics and...
Psoriatic arthritis, or PsA, is a long-term health issue that can hit at any age. It's not just about joint pain—it's a whole package deal of physical and mental challenges. Picture this: you're having a tough time moving around due to inflammation in your joints. Add to that the psychological pressure, like stress and anxiety, and it becomes a real struggle to enjoy...
Imagine you have psoriasis and want to know if you might also get psoriatic arthritis (PsA). Researchers have come up with an interesting way to predict this using data from a big health survey called NHANES. They didn't stick to just one method, but tried out multiple ways to see which works best. This could make it easier for doctors to spot PsA early in people wit...
Psoriasis patients often worry about developing psoriatic arthritis (PsA). But which biologic treatment is best? Researchers looked at three types: IL-23 inhibitors, IL-17 inhibitors, and IL-12/23 inhibitors, comparing them to TNF inhibitors. The goal? To see who's at higher risk for PsA. First, let's talk about what these treatments are. Biologics, like IL-23 and I...